Latest news with #One-India
Time of India
13-05-2025
- Business
- Time of India
Cipla reports 30% increase in net profit, revenue up 9%
Cipla reports 30% increase in net profit, revenue up 9% NEW DELHI: Mumbai-based Cipla has reported a 30% year-on-year (YoY) increase in net profit, standing at Rs 1,222 crore for the fourth quarter ended March 31. The company's revenue was Rs 6,730 crore, reflecting a 9% growth from the corresponding period last year. For FY25, Cipla's revenue rose 8% to Rs 27,548 crore. Umang Vohra, MD and Global CEO, Cipla, commented on the implications of recent US policies in a post results' call, stating, 'We don't see any material impact of tariffs on generics as of now.' Regarding Trump's executive order announced on May 12, he noted, 'as of now, we understand that it's largely targeted at branded drugs. From a generic perspective, generic prices in the US are already significantly comparable with the rest of the world, and even lower in some cases.' Elaborating on the company's performance, he said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track and anchor brands of consumer health business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $934 million. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Business Standard
13-05-2025
- Business
- Business Standard
Cipla registers PAT of Rs 1,222 crore in Q4; EBITDA margin rises to 22.8%
Cipla has reported 30.1% increase in consolidated net profit to Rs 1,222 crore on a 9.2% rise in total income to Rs 6,730 crore in Q4 FY25 as compared with Q4 FY24. On the segmental front, the companys India business revenue was Rs 2,622 crore (up 8% YoY), North America business revenue was Rs 1,919 crore (up 2% YoY), One Africa business revenue was Rs 1,019 crore (up 20% YoY) and the revenue from Emerging Markets and Europe business was Rs 895 crore (up 21% YoY). Further, the API business revenue and that from Others was Rs 182 crore (down 4% YoY) and Rs 92 crore (down 2 YoY), respectively. While EBITDA rose by 16.8% YoY to Rs 1,538 crore, EBITDA margin expanded by 150 basis points YoY to 22.8% in the fourth quarter. The companys R&D investments stood at Rs 426 crore (or 6.3% of sales) for the quarter, driven by product filings and development efforts. For FY25, Cipla has recorded a consolidated net profit of Rs 5,273 crore (up 28.4% YoY) and total income from operations of Rs 27,548 crore (up 8.2% YoY). The pharmaceutical company had a net cash position of Rs 10,369 crore. The debt primarily included lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO, Cipla, said: I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $ 934 million. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The scrip rose 0.40% to currently trade at Rs 1518 on the BSE.
Mint
13-05-2025
- Business
- Mint
Cipla Q4 Results: Profit jumps 30% YoY; declares dividend of ₹13 for FY25, special dividend of ₹3
Cipla Q4 Results: Pharmaceuticals company Cipla on Tuesday, May 13, reported a 30.12 per cent year-on-year (YoY) rise in its Q4FY25 consolidated net profit to ₹ 1,221.84 crore compared to ₹ 939.04 crore in the corresponding quarter of the previous financial year. Revenue from sales rose 8.5 per cent YoY to ₹ 6,597.72 crore from ₹ 6,082.37 crore in Q4FY24. The pharmaceuticals segment clocked a revenue of ₹ 6,503.63 crore in Q4FY25, up 8.5 per cent against ₹ 5,996.38 crore in Q4FY24. Revenue from new ventures increased 35.44 per cent YoY to ₹ 288.48 crore from ₹ 212.99 crore in the same quarter of FY24. EBITDA for the quarter jumped 17 per cent YoY to ₹ 1,538 crore, while EBITDA margin increased 150 bps YoY to 22.8 per cent. For FY25, the company's profit jumped 28 per cent YoY to ₹ 5,273 crore and revenue increased 8 per cent YoY to 27,548 crore. "In FY25, we recorded a revenue growth of 8 per cent over last year with the EBITDA margin of 25.9 per cent, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7 per cent YoY," said Umang Vohra, MD and Global CEO, Cipla. "Key therapies in branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track, and anchor brands of consumer health business maintained leadership position," said Vohra. Vohra pointed out that the US business posted an all-time high annual revenue of $934 million. In One Africa, the company recorded a solid growth of 12 per cent YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15 per cent YoY on the back of a deep market focus strategy. "Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline, as well as focusing on resolutions on the regulatory front,' said Vohra. Meanwhile, the company announced a final dividend of ₹ 13 per equity share for FY25 and a special dividend of ₹ 3 per equity share on the occasion of completing 90 years of the company, taking the total dividend to ₹ 16 per equity share of face value of ₹ 2 each.
